Emerging Focus on COVID-19 Trials to Provide Opportunity for UK Monoclonal Antibodies Market

UK monoclonal antibodies market is estimated to grow at a CAGR of 7.4% during the forecast period. Increasing focus on COVID-19 trials is providing an opportunity for market growth. Monoclonal antibody therapy can particularly target the SARS-CoV-2 virus which makes them more potential compared to other drugs. As a result, the UK research institutes are focusing on clinical trials for this therapy. For instance, in September 2020, The UK National Institute for Health Research (NIHR)-funded RECOVERY trial declared the addition of a new investigational antiviral antibody treatment, which is referred to as REGN-COV2. 

Browse the full report description UK Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Source (Murine, Chimeric, Human, and Humanized), By Application (Cancer, Infectious Diseases, Auto-Immune Diseases, Inflammatory Diseases, and Others) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/uk-monoclonal-antibodies-market

This is the first particularly designed COVID-19 medicine that is investigated in all over the country’s flagship trial into COVID-19 therapeutics among hospitalized patients. Its phase III randomized trial will intend to compare the outcomes of incorporating lab-produced monoclonal antibody combination treatment of Regeneron, REGN-COV2. The drug’s effect on mortality, the requirement for ventilation, and hospital stays will be assessed by the research team. REGN-COV2 includes two monoclonal antibodies (REGN10987 and REGN10933). These therapies are particularly designed by Regeneron scientists to block SARS-CoV-2 infectivity, the virus that causes COVID-19.

Scope of the UK Monoclonal Antibodies Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Source and Application
• Competitive Landscape- AstraZeneca plc, Pfizer Inc., Sitryx Therapeutics Ltd., Orchard Therapeutics plc, and Mylan N.V.

Recent Strategic Initiatives in the UK Monoclonal Antibodies Market

• In July 2020, AstraZeneca plc signed a global development and commercialization agreement with Daiichi Sankyo Company, Ltd. for DS-1062, a proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) of Daiichi Sankyo’s and novel medicine to treat multiple forms of tumor. It is currently in development to treat multiple tumors that commonly show the cell-surface glycoprotein TROP2. 
• In May 2020, AstraZeneca declared that it will partner with ArcherDX, a genomic analysis company engaged in precision oncology. Under the partnership, AstraZeneca will use ArcherDX personalized cancer monitoring which aims to detect minimal residual disease in patients having early-stage non-small cell lung cancer (NSCLC). The assay will be utilized in the Phase III MERMAID-1 trial of AstraZeneca. This intends to assess the outcome of adjuvant treatment with Imfinzi (durvalumab). It is a human monoclonal antibody along with chemotherapy versus chemotherapy alone on disease-free survival. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Monoclonal Antibodies Market-Segmentation

By Source

• Murine
• Chimeric
• Human
• Humanized

By Application

• Cancer
• Infectious Diseases
• Auto-Immune Diseases
• Inflammatory Diseases
• Others